Top

Published in:

Open Access 01-12-2020 | Oral Cancer | Correction

Correction to: Gamma synuclein is a novel nicotine responsive protein in oral cancer malignancy

Authors: Chia-Chen Hsu, Yu-Fu Su, Kuo-Yang Tsai, Feng-Chih Kuo, Chi-Fu Chiang, Chu-Yen Chien, Ying-Chen Chen, Chien-Hsing Lee, Yu-Chiao Wu, Kun Wang, Shyun-Yeu Liu, Yi-Shing Shieh

Published in: Cancer Cell International | Issue 1/2020

Excerpt

Following publication of the original article [1] the authors have notified us of an error in Fig. 5. The incorrect vs. correct Fig. 5 are presented below: …

Hsu C-C, Su Y-F, Tsai K-Y, Kuo F-C, Chiang C-F, Chien C-Y, Chen Y-C, Lee C-H, Wu Y-C, Wang K, Liu S-Y, Shieh Y-S. Gamma synuclein is a novel nicotine responsive protein in oral cancer malignancy. Cancer Cell Int. 2020;20:300. https://doi.org/10.1186/s12935-020-01401-w.CrossRefPubMedPubMedCentral

Title: Correction to: Gamma synuclein is a novel nicotine responsive protein in oral cancer malignancy
Authors: Chia-Chen Hsu
Yu-Fu Su
Kuo-Yang Tsai
Feng-Chih Kuo
Chi-Fu Chiang
Chu-Yen Chien
Ying-Chen Chen
Chien-Hsing Lee
Yu-Chiao Wu
Kun Wang
Shyun-Yeu Liu
Yi-Shing Shieh
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Oral Cancer
Oral Cavity Carcinoma
Published in: Cancer Cell International / Issue 1/2020
Electronic ISSN: 1475-2867
DOI: https://doi.org/10.1186/s12935-020-01478-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2020

Ubiquitin-specific peptide 22 acts as an oncogene in gastric cancer in a son of sevenless 1-dependent manner

Ibrutinib in B-cell lymphoma: single fighter might be enough?

SKP1 promotes YAP-mediated colorectal cancer stemness via suppressing RASSF1

CLEC3B as a potential diagnostic and prognostic biomarker in lung cancer and association with the immune microenvironment

Zoledronic acid inhibits TSC2-null cell tumor growth via RhoA/YAP signaling pathway in mouse models of lymphangioleiomyomatosis

Recent insights into eukaryotic translation initiation factors 5A1 and 5A2 and their roles in human health and disease

Keynote webinar | Spotlight on antibody–drug conjugates in cancer